L. Coughenour

发表

Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization.

H. Tecle, R. Schwarz, J. Kinsora, 1999, The Journal of pharmacology and experimental therapeutics.

Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice

T. Heffner, R. F. Bruns, D. A. Downs, 2004, Psychopharmacology.

8-Substituted 3,4-dihydroquinolinones as a novel scaffold for atypical antipsychotic activity.

M. Walters, L. Coughenour, Jamie M Singer, 2005, Bioorganic & medicinal chemistry letters.

1-[3-(Diarylamino)propyl]piperidines and related compounds, potential antipsychotic agents with low cataleptogenic profiles.

L. Wise, I. Nordin, B. Poschel, 1985, Journal of Medicinal Chemistry.

Novel Muscarinic Agonists for the Treatment of Alzheimer’s Disease

D. T. Dudley, H. Tecle, W. Moos, 1991 .

Effect of antipsychotic and other classes of drugs on spontaneous locomotor activity and neurotoxicity in mice

R. B. Parker, J. McLean, L. Coughenour, 1978, Pharmacology Biochemistry and Behavior.

Excitatory amino acids: 6-phosphonomethyltetrahydro-4-pyrimidinecarboxylic acids and their acyclic analogues are competitive N-methyl-D-aspartic acid receptor antagonists.

Jiang-Ping Wu, C. Bigge, J. Drummond, 1992 .

Examination of a series of 8-[3-[bis(4-fluorophenyl)amino]propyl]-1-aryl-1,3,8- triazaspiro[4.5]decan-4-ones as potential antipsychotic agents.

H. Tecle, L. Wise, D. A. Downs, 1985, Journal of medicinal chemistry.

Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5

W. Moos, M. R. Pavia, R. Davis, 1992 .

1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.

T. Heffner, L. Wise, T. Pugsley, 1987, Journal of medicinal chemistry.

Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.

T. Heffner, L. Wise, T. Pugsley, 1988, Journal of medicinal chemistry.

Exploration of N-phosphonoalkyl-, N-phosphonoalkenyl-, and N-(phosphonoalkyl)phenyl-spaced alpha-amino acids as competitive N-methyl-D-aspartic acid antagonists.

D. Ortwine, F. Marcoux, C. Bigge, 1992, Journal of medicinal chemistry.

New and versatile approaches to the synthesis of CPP-related competitive NMDA antagonists. Preliminary structure-activity relationships and pharmacological evaluation.

C. Bigge, S. Hays, J. Drummond, 1990, Journal of medicinal chemistry.

A specific inhibitor of calcium/calmodulin-dependent protein kinase-II provides neuroprotection against NMDA- and hypoxia/hypoglycemia-induced cell death

K. Wang, F. Marcoux, P. Boxer, 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Subtype selective NMDA receptor antagonists: evaluation of some novel alkynyl analogues.

Jon L. Wright, L. Meltzer, S. Nikam, 2004, Bioorganic & medicinal chemistry letters.

NS 257 (1,2,3,6,7,8-hexahydro-3(hydroxyimino)-N,N,7-trimethyl-2-oxobenzo[2,1-b:3,4-c']dipyrrole-5-sulfonamide) is a potent, systemically active ampa receptor antagonist

E. Nielsen, F. Marcoux, J. Drejer, 1994 .

Exploration of phenyl-spaced 2-amino-(5-9)-phosphonoalkanoic acids as competitive N-methyl-D-aspartic acid antagonists.

F. Marcoux, C. Bigge, J. Drummond, 1989, Journal of medicinal chemistry.

4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist.

J. Hawkinson, S. Espitia, L. Wise, 1999, Journal of medicinal chemistry.

Cholinergic agents: effect of methyl substitution in a series of arecoline derivatives on binding to muscarinic acetylcholine receptors.

H. Tecle, W. Moos, R. Davis, 1992, Journal of Pharmacy and Science.

1-Aminoindanes as novel motif with potential atypical antipsychotic properties.

S. Nikam, L. Coughenour, B. Barr, 2008, Bioorganic & medicinal chemistry letters.

A new device for the rapid measurement of impaired motor function in mice

L. L. Coughenour, J. R. McLean, R. B. Parker, 1977, Pharmacology Biochemistry and Behavior.

Characterization of haloperidol and trifluperidol as subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonists using [3H]TCP and [3H]ifenprodil binding in rat brain membranes.

L. Coughenour, J. Cordon, 1997, The Journal of pharmacology and experimental therapeutics.

Some neurochemical properties of pramiracetam (CI‐879), a new cognition‐enhancing agent

T. Pugsley, Y. Shih, L. Coughenour, 1983 .

Alkyl substituted 3-PPP derivatives. Synthesis and biological investigation

T. Heffner, H. Tecle, L. Wise, 1989 .

Alkyl Substituted 3-PPP Derivatives. Synthesis and Biological Investigation.

T. Heffner, H. Tecle, L. Wise, 1990 .

Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes.

J. Fergus, T. Pugsley, J. Dodd, 1990, Molecular pharmacology.

Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits.

B. Barr, L. Coughenour, Bridget M Barr, 2001, The Journal of pharmacology and experimental therapeutics.

Synthesis and pharmacological evaluation of 4a-phenanthrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor complex.

D. Ortwine, C. Bigge, S. Hays, 1993, Journal of medicinal chemistry.

CI-926 (3-[4-[4-(3-methylphenyl)-1-piperazinyl]butyl]-2,4-imidazolinedione): antihypertensive profile and pharmacology.

D. B. Evans, T. Major, M. J. Ryan, 1986, Journal of Pharmacology and Experimental Therapeutics.

1-(3-(DIARYLAMINO)PROPYL)PIPERIDINES AND RELATED COMPOUNDS, POTENTIAL ANTIPSYCHOTIC AGENTS WITH LOW CATALEPTOGENIC PROFILES

L. Wise, I. Nordin, B. Poschel, 1985 .

CI-943, a potential antipsychotic agent. II. Neurochemical effects.

T. Pugsley, Y. Shih, W. Berghoff, 1989, Journal of Pharmacology and Experimental Therapeutics.